ARQT241018C12500
- 0.05
- 0.000.00%
Arcutis Biotherapeutics Newsroom
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Arcutis Biotherapeutics (ARQT)
Morgan Stanley Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $19
Buy Rating Affirmed for Arcutis Biotherapeutics Amid Positive Dermatology Market Signals
Arcutis Biotherapeutics Analyst Ratings
Jefferies Initiates Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Announces Target Price $15
Buy Rating Initiated on Arcutis Biotherapeutics Amidst Zoryve's Market Expansion and Promising Sales Trajectory
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating
A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $12 to $20
A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $12 to $20
Analysts Offer Insights on Healthcare Companies: Align Tech (ALGN) and Arcutis Biotherapeutics (ARQT)
Arcutis Biotherapeutics Analyst Ratings
Analysts Conflicted on These Healthcare Names: Arcutis Biotherapeutics (ARQT), Gilead Sciences (GILD) and Cardinal Health (CAH)
Arcutis Biotherapeutics: Hold Rating With Cautious Optimism Amid Mixed Financial Signals
Morgan Stanley Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Raises Target Price to $19
Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $18
Buy Rating Affirmed for Arcutis Biotherapeutics Amid Strong Zoryve Launch Prospects
Arcutis Biotherapeutics Analyst Ratings
Needham Reiterates Buy on Arcutis Biotherapeutics, Maintains $18 Price Target
TD Cowen Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $20